Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316097105> ?p ?o ?g. }
- W4316097105 endingPage "1097" @default.
- W4316097105 startingPage "1085" @default.
- W4316097105 abstract "MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor microenvironment. High expression of IL4R is associated with poor clinical outcomes.MDNA55-05 is an open-label, single-arm phase IIb study of MDNA55 in recurrent GBM (rGBM) patients with an aggressive form of GBM (de novo GBM, IDH wild-type, and nonresectable at recurrence) on their 1st or 2nd recurrence. MDNA55 was administered intratumorally as a single dose treatment (dose range of 18 to 240 ug) using convection-enhanced delivery (CED) with up to 4 stereo-tactically placed catheters. It was co-infused with a contrast agent (Gd-DTPA, Magnevist®) to assess distribution in and around the tumor margins. The flow rate of each catheter did not exceed 10μL/min to ensure that the infusion duration did not exceed 48 h. The primary endpoint was mOS, with secondary endpoints determining the effects of IL4R status on mOS and PFS.MDNA55 showed an acceptable safety profile at doses up to 240 μg. In all evaluable patients (n = 44) mOS was 11.64 months (80% one-sided CI 8.62, 15.02) and OS-12 was 46%. A subgroup (n = 32) consisting of IL4R High and IL4R Low patients treated with high-dose MDNA55 (>180 ug) showed the best benefit with mOS of 15 months, OS-12 of 55%. Based on mRANO criteria, tumor control was observed in 81% (26/32), including those patients who exhibited pseudo-progression (15/26).MDNA55 demonstrated tumor control and promising survival and may benefit rGBM patients when treated at high-dose irrespective of IL4R expression level.Trial Registration: Clinicaltrials.gov NCT02858895." @default.
- W4316097105 created "2023-01-14" @default.
- W4316097105 creator A5000664633 @default.
- W4316097105 creator A5001112274 @default.
- W4316097105 creator A5003877580 @default.
- W4316097105 creator A5014234836 @default.
- W4316097105 creator A5014523073 @default.
- W4316097105 creator A5017095860 @default.
- W4316097105 creator A5025351354 @default.
- W4316097105 creator A5025857887 @default.
- W4316097105 creator A5037596103 @default.
- W4316097105 creator A5039448543 @default.
- W4316097105 creator A5040686327 @default.
- W4316097105 creator A5044802659 @default.
- W4316097105 creator A5046719798 @default.
- W4316097105 creator A5049126969 @default.
- W4316097105 creator A5053423644 @default.
- W4316097105 creator A5063863193 @default.
- W4316097105 creator A5064016407 @default.
- W4316097105 creator A5069589605 @default.
- W4316097105 creator A5069602781 @default.
- W4316097105 creator A5076149776 @default.
- W4316097105 creator A5076877923 @default.
- W4316097105 creator A5083922162 @default.
- W4316097105 creator A5090305344 @default.
- W4316097105 date "2023-01-14" @default.
- W4316097105 modified "2023-10-16" @default.
- W4316097105 title "Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial" @default.
- W4316097105 cites W1673454808 @default.
- W4316097105 cites W1989269073 @default.
- W4316097105 cites W1992639272 @default.
- W4316097105 cites W1993725418 @default.
- W4316097105 cites W1994024307 @default.
- W4316097105 cites W2004376103 @default.
- W4316097105 cites W2007881147 @default.
- W4316097105 cites W2008854570 @default.
- W4316097105 cites W2013816626 @default.
- W4316097105 cites W2025435159 @default.
- W4316097105 cites W2037342239 @default.
- W4316097105 cites W2054569460 @default.
- W4316097105 cites W2066565322 @default.
- W4316097105 cites W2074475151 @default.
- W4316097105 cites W2085475378 @default.
- W4316097105 cites W2092327903 @default.
- W4316097105 cites W2121396361 @default.
- W4316097105 cites W2124736921 @default.
- W4316097105 cites W2125643269 @default.
- W4316097105 cites W2126817554 @default.
- W4316097105 cites W2132697290 @default.
- W4316097105 cites W2149768128 @default.
- W4316097105 cites W2156330848 @default.
- W4316097105 cites W2159864492 @default.
- W4316097105 cites W2163458899 @default.
- W4316097105 cites W2170367762 @default.
- W4316097105 cites W2197484396 @default.
- W4316097105 cites W2329199594 @default.
- W4316097105 cites W2558944992 @default.
- W4316097105 cites W2569426717 @default.
- W4316097105 cites W2577801124 @default.
- W4316097105 cites W2597570800 @default.
- W4316097105 cites W2604221352 @default.
- W4316097105 cites W2768158625 @default.
- W4316097105 cites W2768388636 @default.
- W4316097105 cites W2916454046 @default.
- W4316097105 cites W2947007067 @default.
- W4316097105 cites W2947893655 @default.
- W4316097105 cites W2950385718 @default.
- W4316097105 cites W3026551532 @default.
- W4316097105 cites W3153537663 @default.
- W4316097105 cites W3202623877 @default.
- W4316097105 cites W4210899445 @default.
- W4316097105 cites W2098678529 @default.
- W4316097105 doi "https://doi.org/10.1093/neuonc/noac285" @default.
- W4316097105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36640127" @default.
- W4316097105 hasPublicationYear "2023" @default.
- W4316097105 type Work @default.
- W4316097105 citedByCount "5" @default.
- W4316097105 countsByYear W43160971052023 @default.
- W4316097105 crossrefType "journal-article" @default.
- W4316097105 hasAuthorship W4316097105A5000664633 @default.
- W4316097105 hasAuthorship W4316097105A5001112274 @default.
- W4316097105 hasAuthorship W4316097105A5003877580 @default.
- W4316097105 hasAuthorship W4316097105A5014234836 @default.
- W4316097105 hasAuthorship W4316097105A5014523073 @default.
- W4316097105 hasAuthorship W4316097105A5017095860 @default.
- W4316097105 hasAuthorship W4316097105A5025351354 @default.
- W4316097105 hasAuthorship W4316097105A5025857887 @default.
- W4316097105 hasAuthorship W4316097105A5037596103 @default.
- W4316097105 hasAuthorship W4316097105A5039448543 @default.
- W4316097105 hasAuthorship W4316097105A5040686327 @default.
- W4316097105 hasAuthorship W4316097105A5044802659 @default.
- W4316097105 hasAuthorship W4316097105A5046719798 @default.
- W4316097105 hasAuthorship W4316097105A5049126969 @default.
- W4316097105 hasAuthorship W4316097105A5053423644 @default.
- W4316097105 hasAuthorship W4316097105A5063863193 @default.
- W4316097105 hasAuthorship W4316097105A5064016407 @default.
- W4316097105 hasAuthorship W4316097105A5069589605 @default.
- W4316097105 hasAuthorship W4316097105A5069602781 @default.